Visible results with DUPIXENT

In DUPIXENT clinical trials including adolescents, the primary endpoint was the proportion of subjects with an Investigator’s Global Assessment (IGA) of 0 (clear) or 1 (almost clear) and a ≥2-point improvement at Week 16.1

Actual 12-year-old patient in the phase 3 adolescent DUPIXENT trial. Patient had a baseline IGA of 4 and EASI of 31. Individual results may vary.

Patient 1: Adolescent patient achieved a 2-point improvement in IGA

DRAG TO SEE
RESULTS

A clinical responder was defined as a patient achieving IGA 0 or 1 and at least a 2-point improvement from baseline.1

  • This adolescent patient did not meet the primary endpoint in the clinical trial based on their IGA score at Week 16

SIGNIFICANT SKIN CLEARANCE (PRIMARY ENDPOINT; P <0.001)1-3,a

Efficacy results of DUPIXENT at Week 16 in AD‑1526b
DUPIXENT
(n=82)c
PLACEBO
(n=85)
Achieved clear or almost‑clear skin
(IGA 0 or 1)
24% 2%

aResponder was defined as a subject with an IGA 0 or 1 (clear or almost clear) and a reduction of ≥2 points on a 0‑4 scale at Week 16 (primary efficacy outcome).1

bFull Analysis Set includes all subjects randomized.1

cAdolescents ≥60 kg received DUPIXENT 300 mg Q2W after a 600 mg loading dose, and adolescents <60 kg received 200 mg Q2W after a 400 mg loading dose.1

IGA assesses the overall severity of the clinical signs of atopic dermatitis3

A 0- to 4-point scoring system of the overall severity of atopic dermatitis skin lesions3


4

Severe
Disease

Severe erythema and severe
papulation/infiltration

3

Moderate
Disease

Moderate erythema and moderate
papulation/infiltration

2

Mild
Disease

Mild erythema and mild
papulation/infiltration

1

Almost
Clear

Just perceptible erythema, and
just perceptible papulation/infiltration

0

Clear
 

No inflammatory signs of atopic dermatitis 

A clinical responder
was defined as a
patient achieving
IGA 0 or 1 and at least a
2-point improvement
from baseline1

IGA, Investigator's Global Assessment.
Example representation of IGA scoring.
Not an actual patient.